EUCARBON

Pays: Israël

Langue: anglais

Source: Ministry of Health

Ingrédients actifs:

MEDICINAL CHARCOAL; RHUBARB; SENNAE FOLIUM; SULFUR PURIFIED

Disponible depuis:

TRUPHARM MARKETING 1985 LTD.

Code ATC:

A07BA51

forme pharmaceutique:

TABLETS

Composition:

SENNAE FOLIUM 105 MG; RHUBARB 25 MG; SULFUR PURIFIED 50 MG; MEDICINAL CHARCOAL 180 MG

Mode d'administration:

PER OS

Type d'ordonnance:

Required

Fabriqué par:

F. TRENKA CHEM-PHARM FABRIC, AUSTRIA

Groupe thérapeutique:

MEDICINAL CHARCOAL, COMBINATIONS

Domaine thérapeutique:

MEDICINAL CHARCOAL, COMBINATIONS

indications thérapeutiques:

Mild laxative, anti-flatulant.

Date de l'autorisation:

2021-04-30

Résumé des caractéristiques du produit

Page 1 of 4
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
EUCARBON
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1 tablet contains:
Senna folium
105 mg
Rhubarb
25 mg
Medicinal charcoal
180 mg
Purified sulfur
50 mg
Excipient with known effect:
Each tablet contains 43.4 mg of sucrose.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Black, round tablets.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Mild laxative, anti-flatulent
.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
POSOLOGY
Adolescents over 12 years of age, adults, elderly
1-2 tablets with or after meals with liquid up to 3 times daily to
obtain a laxative and purgative effect. If a stronger
laxative effect is desired, the evening dose can be increased to 3-4
tablets of the product.
Herbal substance/preparation corresponding to 2.65 to 3.95 mg of
hydroxyanthracene glycosides (calculated as
Rhein) in one tablet.
The maximum daily dose of hydroxyanthracene glycosides is 30 mg. This
is equivalent to 8 tablets. The correct
individual dose is the smallest required to produce a comfortable
soft-formed motion.
Paediatric population
The use in children under 12 years of age is contraindicated (see
section 4.3 Contraindications).
METHOD OF ADMINISTRATION
For oral use.
Page 1 of 4
DURATION OF USE
Use for more than 1-2 weeks requires medical supervision.
If the symptoms persist during the use of the medicinal product, a
doctor or a pharmacist should be consulted.
See
also section 4.4 Special warnings and precautions for use.
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance(s) or to any of the
excipients listed in section 6.1.
Intestinal obstruction, acute inflammatory diseases of the intestine,
abdominal pain of unknown origin.
Severe disorders of water and electrolyte balance.
Pregnancy and lactation (see section 4.6 and 5.3).
Children under 12 years of age.
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
The dose necessary for a safe effect can vary individually. The
occurrence of diarrhoea is a sign of ove